Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xigris Medicare Reimbursement: CMS Resisting New Severe Sepsis Code

Executive Summary

The Centers for Medicare & Medicaid Services plans to reimburse Lilly's sepsis agent Xigris using existing reimbursement codes

You may also be interested in...



Guilford Expects Medicare Payment Boost For Gliadel Starting Oct. 1

A new Medicare hospital payment category covering Guilford's Gliadel Wafer is expected to raise the reimbursement rate for the chemotherapy implant effective Oct. 1

Guilford Expects Medicare Payment Boost For Gliadel Starting Oct. 1

A new Medicare hospital payment category covering Guilford's Gliadel Wafer is expected to raise the reimbursement rate for the chemotherapy implant effective Oct. 1

Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities

Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel